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Cell proliferation is a delicately regulated process that couples 
growth signals and metabolic demands to produce daughter 
cells. Interestingly, the proliferation of tumor cells immensely 
depends on glycolysis, the Warburg effect, to ensure a sufficient 
amount of metabolic flux and bioenergetics for macromolecule 
synthesis and cell division. This unique metabolic derangement 
would provide an opportunity for developing cancer therapeutic 
strategy, particularly when other diverse anti-cancer treatments 
have been proved ineffective in achieving durable response, 
largely due to the emergence of resistance. Recent advances in 
deeper understanding of cancer metabolism usher in new 
horizons of the next generation strategy for cancer therapy. 
Here, we discuss the focused review of cancer energy 
metabolism, and the therapeutic exploitation of glycolysis and 
OXPHOS as a novel anti-cancer strategy, with particular 
emphasis on the promise of this approach, among other cancer 
metabolism targeted therapies that reveal unexpected 
complexity and context-dependent metabolic adaptability, 
complicating the development of effective strategies. [BMB 
Reports 2014; 47(3): 158-166]
CANCER METABOLISM: THE WARBURG EFFECT 
REKINDLED, AND REVISITED
The pathognomonic feature of cancer is virtually unlimited 
growth and propagation (local and metastatic growth) of malig-
nant cells. Uncontrolled cancer cell proliferation requires both 
oncogenic aberrant growth signals, and sufficient metabolic 
provision of bioenergetics and biosynthetic precursors. 
Intriguingly, the metabolic flux is principally derived from the 
glucose in cancer cells, known as the Warburg effect. Unlike 
normal cells, which can also burn amino acids and fatty acids 
for energy, cancer cells seem ‘addicted’ to glucose, which 
serves as both a principal energy source, and the cellular 
building blocks required for cell proliferation. Recent advances 
in molecular imaging technology provide compelling clinical 
evidence that cancer tissues vividly uptake glucose, and dis-
play increased glycolysis, compared to neighboring normal tis-
sues, by 18-FDG PET scan (1), reflecting dysregulated glucose 
metabolism in cancer cells. Considering the high growth and 
proliferation rate of cancer cells, an unusual amount of meta-
bolic flux is indispensable to meet the need for rapid provision 
of ATP and intermediary metabolites, for macromolecule syn-
thesis, such as nucleotides, lipids, and proteins. Thus a high 
glycolytic feature should allow cancer cells to have a selective 
growth advantage, in terms of bioenergetics and biosynthesis.
　In 1920s, Warburg pioneered the investigation of the tumor 
cell energetics metabolism, and reported that tumor cells pro-
duce a large amount of lactate, even in the presence of oxygen 
(2). Glycolysis, conversion of glucose to lactate, only produces 
two ATP molecules, compared to 36 for the complete oxida-
tion of glucose to CO2 and H2O. Thus, incomplete oxidation 
of glucose to lactate yields only 5% of the energy available 
from glucose. Considering the immense metabolic necessity 
for cancer cells, this phenomenon poses a paradox: Why do 
cancer cells, which obviously are in great demand for ATP and 
intermediary metabolites, heavily depend on such a wasteful 
version of metabolism? This apparently senseless waste of glu-
cose prompted Warburg to postulate a hypothesis, that a de-
fect in mitochondrial respiration is the ultimate cause of can-
cer, the Warburg theory (3); although it has been discredited .
　Accumulating evidence suggests that malignant trans-
formation is associated with alterations in cellular metabolism, 
and cancer-associated metabolic derangement is linked to the 
activation of oncogenes, and to the inactivation of tumor sup-
pressor genes (4, 5). Subsequently, it has now become clear 
that the Warburg effect is, at least in part, the outcome of a 
complex and intricate network of signaling pathways, which 
once used to be regarded as a separate entity of cell biology. 
Further, the Warburg effect represents only one aspect of mul-
tifaceted cancer-associated metabolism, which spans from 
aerobic glycolysis, increased pentose phosphate pathway 
(PPP), increased macromolecule biosynthesis, through redox 
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homeostasis, to autophagy (6). Although the detailed mecha-
nistic link between oncogenic growth signaling and the con-
trol of cancer-associated metabolism is not yet fully unveiled, 
it is now widely accepted that the signal transduction that con-
trols tumor cell growth, and cancer metabolism, are closely in-
terconnected (7). One of the frequently deranged growth factor 
signals in cancer, phosphatidylinositol 3-kinase (PI3K)-AKT/ 
PKB signaling, is important in the physiological role of insulin 
in normal cells (8). The insulin-PI3K-AKT/mammalian target of 
rapamycin (mTOR) pathway plays a critical role in coupling 
the energy status, and cellular growth. In animals, this mecha-
nism provides the central metabolic homeostasis in nutrient 
sensing, and the regulation of cell growth, in response to envi-
ronmental nutrient fluctuations.
　Indeed, the PI3K-AKT/mTOR signaling axis is a well-known 
principal cellular growth signaling pathway, and its aberrant 
activation is reported across many cancer types (9), establish-
ing a relationship between tumor growth signaling, and central 
metabolism.
　Another example of this intricate interconnection between 
oncogenic drivers and cancer metabolism is Myc, a pleiotropic 
transcription factor, and multi-function oncoprotein. Myc is 
known to stimulate glucose uptake (10) and expression of the 
M2 isoform of muscle-type pyruvate kinase (PK-M2), but it also 
leads to glutaminolysis, by complex transcriptional and 
post-transcriptional regulations (11, 12). Oncogenic Ras and 
Raf mutations are also associated with increased expression of 
glucose transporter 1 (GLUT1) (13), allowing cancer cells to 
survive a glucose limited tumor microenvironment (14, 15).
　As exemplified by the interconnection between typical onco-
genes and tumor metabolic regulation, tumor suppressor genes 
also have intimate relationship with cancer-associated metabol-
ic aberrations. For example, p53 mutation, which occurs in 
more than 50% of all human cancers, results in a diverse spec-
trum of metabolic ramifications that stimulate glycolysis. 
Indeed, wild type p53 is able to transcriptionally repress the ex-
pression of a couple of GLUTs, GLUT1 and GLUT4 (16). 
Further, p53 stimulates the expression of TP53-induced gly-
colysis and apoptosis regulator (TIGAR) (17), glutaminase 2 
(GLS2) (18), and synthesis of cytochrome c oxidase 2 (SCO2), 
along with various pro-autophagic genes (19, 20). Among 
these, TIGAR functions as a Fructose-2,6 bisphosphatase, 
which reduces fructose-2,6 bisphosphate, the allosteric activa-
tor of 6-phosphofructo kinase (PFK), a second committed en-
zyme in glycolysis, diverting metabolic flux towards pentose 
phosphate pathway (PPP), thereby decreasing glycolysis (21). 
Further, SCO2 is crucial for the assembly of the cytochrome c 
oxidase (COX) complex, a critical molecular player in oxidative 
phosphorylation, explaining why p53-deficient cells exhibit re-
duced baseline levels of mitochondrial energy transduction 
(19). The p53 system also cross-talks with PI3K-PTEN-AKT sig-
naling pathway, thereby modulating their metabolic functions 
(5). Notably, p53 has recently been revealed to aid the adaptive 
response of cancer cells to serine and glutamine shortage (22, 
23), indicating that p53-deficeint cancer cells may require an 
ample supply of these amino acids, to support their survival 
and proliferation. Further research is required to document that 
the therapeutic exploitation of serine or glutamine deprivation, 
specific to cancer cells with p53 deficient tumors, is clinically 
feasible.
　Taken together, these observations indicate that cancer 
growth is intimately connected to metabolic regulation by di-
verse oncogenes and oncosuppressors. Further, the cross-talk 
between tumor-relevant genes and glycolytic enzymes pro-
vides potential molecular explanations of why cancer cells ex-
hibit the Warburg effect, a seemingly senseless wasteful ver-
sion of metabolism, despite heightened metabolic demands.
TARGETING CANCER METABOLISM
During the past decade, the understanding of cancer-associated 
metabolic rewiring has been deepened, and this metabolic de-
rangement of cancer cells has recently been viewed as a novel 
therapeutic target (Fig. 1). Several different approaches to tackle 
this Achilles’ heel of cancer have been explored, with some ex-
tent of preclinical successes, resulting in the identification of 
drug candidates that are now being evaluated through clinical 
trials (24). A detailed compendium of such metabolic targets 
and therapeutics is beyond the scope of this mini Review, and 
has been covered elsewhere in the literature.
　One of the prototypical metabolic inhibitors used to treat 
cancer is 2-deoxy-D-glucose (2DG). 2DG serves a couple of 
distinct roles, in terms of core energy metabolism. First, it 
competes with naïve glucose for GLUTs, which enhance the 
facilitated diffusion of glucose inside the cell, thereby decreas-
ing glucose uptake by cancer cells. Second, the unselective in-
hibition of hexokinase (HK), which is the first committed en-
zyme, and which entraps glucose inside the cell by phosphor-
ylation, further decreases the overall glycolytic flux. Once 
phosphorylated by HK, the 2DG is a dead-end metabolite that 
is not allowed to be involved in downstream metabolism (25, 
26). Theoretically, 2DG is an attractive candidate for inhibiting 
the Warburg effect; however, 2DG alone has proven un-
successful in clinical evaluation, and subsequent trials have fo-
cused on combination strategy, with conventional chemo-
therapeutics (27), or radiotherapy (28).
　A large body of preclinical researches suggests that several 
enzymes and transporters in cancer-associated metabolic circui-
tries, such as glycolysis, the TCA cycle, lipid biogenesis, and 
glutaminolysis, may be potential drug targets. These include 
HK2 (29), PFKFB3 (30), GAPDH (31), PK-M2 (32), LDHA (33), 
GLUT1 (34), GLUT4 (35), and monocarboxylate transporter 4 
(MCT4, SLC16A4) (36, 37). Among these, small molecule in-
hibitors of PFKFB3 have been shown to suppress the growth of 
breast cancer cells and promyelocytic leukemia cells xeno-
grafted in immune compromised mice (38). Further, it inhibits 
the development of murine lung cancer transplanted to immune 
competent hosts (39). Similarly, the pharmacological or genetic 
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Fig. 1. Schematic representation of cancer energy metabolism and potential bioenergetics targeted strategy. Simplified overall metabolic net-
work features are illustrated. In tumor cells, enhanced metabolic fluxes are highlighted with orange lines. When glycolysis is inhibited by 
2DG, the metabolic flux to TCA cycle and OXPHOS (Oxidative phosphorylation) is increased. Metformin, which inhibits ETC complex I 
(NADH dehydrogenase complex), a major entry point of electron to electron transfer chain, can suppress tumor cell bioenergetics by de-
creasing ATP generation, through OXPHOS complementary to glycolysis inhibitors.
intervention of HK2 (29), GAPDH (40), PK-M2 (32), LDHA (33), 
GLUT1 (34), GLUT4 (35), and MCT4 (36) have demonstrated in 
vivo anti-cancer effects in several tumor models. Of note, prom-
ising preclinical results have been reported with HK2 inhibition 
using 3-bromopyruvate (3-BP) (41) and methyl jasmonate, in a 
range of rodent human tumor xenograft models (42). However, 
subsequent studies revealed that the specificity of 3-BP for HK2 
is limited: 3-BP has been shown to inhibit GAPDH and LDH, at 
least, among other glycolytic enzymes (41, 43), complicating 
the further clinical development. In line with this, the develop-
ment of another HK2 inhibitor lonidamine once was promising, 
but has failed to prove clinical efficacy in clinical trials (44-46).
　Despite early enthusiasm, only a small number of metabolic 
inhibitors have advanced to clinical development. One of these 
winners, a PK-M2 inhibiting approach, has been assessed as a 
single therapeutic agent, in patients with metastatic renal cell 
carcinoma and recurrent skin cancers (ClinicalTrials.gov identi-
fiers: NCT00735332; NCT00422786). PK-M2 is one of the 
three committed enzymes in glycolysis, making this enzyme a 
promising therapeutic target, as is the case with HK2 and 
PFKBP3. Notably and paradoxically, however, PK-M2 activa-
tion is also being investigated for another anti-cancer ther-
apeutic strategy in preclinical setting (47). Further, recent evi-
dence suggests that PK-M2 is not required for some form of tu-
mors to proliferate, indicating the dispensability (48), and cel-
lular context-dependency, of this enzyme. Collectively, these 
results make cancer metabolic enzyme targeted therapy diffi-
cult to advance into clinical developments.
　Another cancer specific metabolic alteration, Glutaminolysis, 
that cancer cells also depend heavily on glutamine for pro-
liferation and survival (49, 50), prompted the evaluation of glu-
tamine addiction in cancer. Glutaminase 1 (GLS1) targeting 
agents have been demonstrated to selectively suppress the ma-
lignant transformation of murine fibroblast induced by GTPase 
of the RHO family protein, and to inhibit the growth of human 
breast cancer, B cell lymphoma and glioma cells (51, 52). It is 
thought that glutamine might provide both carbon and nitrogen 
sources to tumor cells’ either baseline or proliferative phase re-
quirement of those essential metabolic atoms. Indeed, gluta-
mine can feed the TCA cycle (i.e. anaplerosis), by being con-
verted to α-KG catalyzed by glutamine dehydrogenase 1 
(GLUD1). Interestingly, RNAi-mediated knock down or phar-
macological inhibition of GLUD1 shifts the metabolic scheme 
of cultured glioblastoma cells from glutamine to glucose (53), 
indicating that the metabolic adaptation of tumor cells, once 
thought “addicted”, quite frequently takes place.
　Taken together, these metabolic adaptabilities, redundancy 
in similar metabolic modules, and circumventing pathways in-
terconnected with the unique molecular make-up of individual 
tumors, complicate the development of clinically usable meta-
bolic targeted therapeutics.
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Fig. 2. Integrated signaling networks and tumor cellular bioenergetics. Tumor cell growth and survival require both oncogenic growth signals 
and sufficient metabolic flux that supports both biosynthesis of macromolecules like nucleotides, proteins and lipids, as well as ATP 
production. Oncogenic growth factor receptor signaling conveyed through PI3K-Akt can upregulate glycolysis, thereby providing sufficient cel-
lular bioenergetics to support mTOR mediated cancer progression. AMPK signaling senses cellular energy stress, and downmodulates en-
ergy-consuming processes (e.g. mTOR driven biosynthetic pathways). The LKB1-AMPK pathway and PI3K-AKT-mTOR pathway have a cross-talk 
through a molecular convergence point TSC2, consolidating the emerging intimate relationship between physiological control of metabolism 
and cancer growth.
TUMOR CELLULAR BIOENERGETICS AND ENERGY 
SENSING SIGNALING PATHWAY
As discussed above, the clinical development of cancer-asso-
ciated metabolism targeted drugs has been faltering, despite 
the initial enthusiasm since the Warburg effect has trium-
phantly been revisited.
　Among others, the unexpected metabolic flexibility, re-
dundancy in metabolic network, and emergence of circum-
venting strategy by cancer cells are the major culprits. Further, 
several agents that were apparently promising at the pre-
clinical stage have failed to enter the clinical development, 
due to unacceptable high toxicity, such as hepatotoxicity 
caused by carnitine palmitoyltransferase 1A (CPT1) inhibitor 
etomoxir (54).
　In this context, the Warburg effect itself is still an attractive 
therapeutic target over many metabolic enzymes, since many 
cancers exhibit glycolytic phenotype. An accumulating body 
of evidence indicates that the tumor bioenergetics are primar-
ily derived from glucose in most tumor types, consolidating 
the idea that blocking glucose utility holds promise in cancer 
therapy. Clinically, tumors with high glucose uptake detected 
by the FDG-PET scan demonstrate a worsened outcome (55), 
further underscoring the therapeutic potential of the inhibition 
of glycolysis.
　Cellular energetics are primarily supplied by either glycolysis, 
or mitochondrial oxidative phosphorylation (OXPHOS). Consi-
dering the clinical demonstration of high glycolytic phenotype 
of most tumors, it looks reasonable that drugging the Warburg 
effect could result in an effective anti-cancer effect. Indeed, 
many malignant cells have a demonstrably greater sensitivity to 
glucose deprivation-induced cytotoxicity than normal cells (56). 
An inhibitor of glycolysis, 2DG is a glucose analog that cannot 
be metabolized, and that is a useful drug of many diseases, in-
cluding autosomal dominant polycystic kidney disease (27), and 
cancer. In spite of promising preclinical results, however, in 
clinical studies on its own, 2DG failed to realize its expectation.
　Subsequently, in experimental cancer therapeutics, 2DG is 
now used in combination with radiotherapy or classical cyto-
toxic anticancer drugs (28, 57). It is highly speculated that the 
concentrations of 2DG used in preclinical evaluation do not 
represent clinical dose, as most in vitro studies utilized 
non-physiological levels of 2DG, ranging from 8-100 mM. In 
reality, the acceptable level of 2DG in clinical setting might be 
4-5 mM, which can maintain the molar ratio between naïve 
glucose to 2DG at approximately 1：1 (58). As a result, clin-
ically applicable doses of 2DG make cell growth slower, but 
rarely cause cell death in vitro and in vivo, when used alone 
(59, 60).
　Indeed, when these clinically achievable concentrations of 
2DG were used in vitro, the anti-cancer effect was not sub-
stantial, across a broad range of human cancer cell lines (61). 
Further, 2DG at the clinical doses did not substantially activate 
AMP-activated kinase (AMPK), reflecting insufficient sup-
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pression of tumor bioenergetics. AMPK, which is a conserved 
serine/threonine protein kinase, maintains and monitors energy 
homeostasis, as a cellular energy sensor and signal transducer 
(62, 63). AMPK phosphorylates many substrates that modulate 
the balance between intracellular energy levels and cellular 
metabolic status, switching from anabolic to catabolic metabo-
lism during energy stress period (64). Among the downstream 
substrates of AMPK, tuberous sclerosis complex 1 and 2 
(TSC1/2), as well as Acetyl CoA carboxylase (ACC1 and 2), 
have particular importance in cancer. mTOR pathway con-
stitutes a key cellular growth machinery, transducing signals to 
promote protein synthesis and cell cycle progression (65). 
mTOR activity is positively regulated by upstream AKT, which 
phosphorylates and suppresses TSC1/2, thereby reversing its in-
hibitory effect on mTOR. On the other hand, AMPK activates 
TSC1/2, resulting in mTOR signaling downregulation. In this 
way, AMPK activation can switch off the cell’s major growth 
signaling and biosynthetic pathway, to stringently keep energy 
expenditure in control (Fig. 2). Further, AMPK-mediated mTOR 
suppression activates autophagy, which serves the catabolic 
mobilization of endogeneous energy substrates, such as ribo-
some, obsolete subcellular organelles - aged mitochondria for 
example - portion of cytosol, and lipid membrane, and de-
grades them in the lysosome.
　ACC1 and ACC2 are also phosphorylated and inhibited by 
AMPK. Since ACC1/2 catalyze the first step of fatty acid bio-
genesis by carboxylating acetyl-CoA, inhibition of their cata-
lytic activity by AMPK serves a gatekeeper role in fatty acid 
synthesis (66).
　Taken together, AMPK activation suppresses energy-con-
suming anabolic metabolism, and shifts toward energy-gen-
erating catabolic metabolism, indicative of a bioenergetics 
stress induced salvage mechanism.
　Recently, it has been demonstrated that glucose deprivation 
of cultured cancer cells results in the activation of AMPK sig-
naling system (67-69). Further, the AMPK activation by AICAR, 
an AMP-mimetic thus mechanism specific, leads to transcrip-
tional reprogramming, favoring augmentation of mitochondrial 
OXPHOS, by the coordinated upregulation of genes encoding 
ETC complexes and TCA cycle (58). Subsequent functional 
analysis of mitochondrial energy generation and cellular phe-
notype assay confirmed that AMPK activation provides pro-
tective effect on cancer cells in bioenergetics stress (70). To as-
sess the role of AMPK in glucose deprivation context, AMPK-/- 
MEFs were cultured in either glucose repleted or deprived me-
dia, and confirmed that AMPK indeed protects cells from 
apoptosis in glucose depleted culture. This observation poses a 
clinically important notion that AMPK is a double-edged 
sword, which might act as a tumor suppressor, or a pro-onco-
genic regulator, depending on the cellular energetic context. 
Indeed, when tumor cells are in proliferative phase, when nu-
trients are ample, and matched with growth promoting signals, 
AMPK can exert tumor suppressive effect, through inhibition 
of mTOR. In contrast, when tumor cells are in energy stress 
condition, AMPK can promote the survival of tumor cells, by 
shifting energy pathway to OXPHOS. Therefore, AMPK-activat-
ing drugs should be carefully used, considering the tumor bio-
energetic status; and the improved understanding of AMPK ef-
fects on cancer progression should be further investigated.
TARGETING BIOENERGETICS: DRUGGING THE 
WARBURG EFFECT AND COMPENSATORY 
MECHANISM
Recently, Sahra et al. (71) and Cheong et al. (61) reported the 
anti-cancer effect of a combination of 2DG and metformin to 
target cancer energy metabolism. The fundamental concept of 
their approaches is to target two sources of cellular bio-
energetics, thereby suppressing tumor growth, and inducing 
cell death.
　Metformin is a biguanide drug, widely used for the treat-
ment of type-2 diabetes, which is known to increase insulin 
sensitivity, and to lower hyperglycemia (72). Metformin has 
been known to inhibit mitochondrial ETC complex I activity, 
thereby indirectly activating AMPK, as a result of ATP deple-
tion (73). So far, mechanisms of the action of metformin have 
been reported in diverse ways. Among those, the inhibition of 
cancer cell growth through regulation of LKB1-AMPK signaling 
or mTOR signaling have mostly been reported. AMPK phos-
phorylates and activates tumor suppressor gene, p53, which 
causes the inhibition of cell division, and induced apoptosis. 
Unfolded protein response (UPR) is a complex signaling net-
work, and metformin selectively disrupted UPR transcriptional 
activity, by mimicking glucose deprivation (74). In their report, 
Cheong et al. provided compelling evidence that metformin 
actually coordinately downregulates genes encoding ETC com-
plex I (61). This observation is in line with previous reports, 
and further suggests the potential explanations of how metfor-
min exerts inhibitory effect on mitochondrial respiration. In 
the absence of glycolysis, mitochondrial OXPHOS is the only 
potential source for ATP generation. Therefore, when in-
hibition of glycolysis with 2DG is combined with a com-
promise of mitochondrial energy transduction pathway with 
metformin, it would result in bioenergetics crisis, leading to 
cell death. Interestingly, a combination of metformin and 2DG 
induced significant amount of autophagy, leading to cell de-
mise at later time point, in cultured cancer cells (61). This is 
somewhat discordant from the observations by Sahra et al., 
where they showed that the combination shifts surviving au-
tophagy to apoptosis (71). However, these observations are 
evident in p53-dependent manner; thus, further investigation 
of the mode of action should be warranted, in the range of tu-
mor cells harboring p53 mutations.
　Regardless, a combination strategy using 2DG and metfor-
min showed in vivo efficacy, and the combination should be 
readily applicable to clinical test, since these two drugs have 
been used in clinic for a long time, without demonstrable seri-
ous toxicities. 
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　In the foreseeable future, drugs targeting metabolic enzymes 
in biogenesis or anabolic metabolism are far fetching, since re-
dundancy and circumventing metabolic networks might exist, 
hampering the clinical benefit, while imposing unexpected 
toxicity to normal cells, which do not have such metabolic re-
dundancy, or have only limited circumventing mechanisms.
　In contrast, targeting bioenergetics with agents that smartly 
exploit tumor-cell specific traits, such as tumor mitochondrial 
transmembrane potential and CPT1 expression, thereby spar-
ing normal cells from unwanted collateral damage, can be a 
promising low-hanging fruit, which can deliver immediate 
clinical benefit.
CONCLUDING REMARKS
The Warburg effect confers metabolic advantages on tumor 
cells. Increased glycolysis is driven by oncogenic pathways 
that allow tumor cells to couple growth machinery and bio-
mass production. Consequently, drugging the Warburg effect 
seems a promising therapeutic target. However, realizing the 
clinical benefit of drugging the Warburg effect requires simul-
taneous blockade of the mitochondrial oxidative energy 
pathway.
　Further, comprehensive understanding of the cross-talk be-
tween signaling pathways and metabolic control in cancer 
cells, could extend the current molecular targeted therapy to a 
combinatorial strategy with cancer metabolic manipulation.
　Importantly, the genetic alterations unique to individual can-
cer types should be assessed; thereby, how genomic changes 
influence, and modify the response to bioenergetics targeted 
therapy. Regardless, it is not easily foreseeable that cancer 
cells circumvent energy-targeted therapeutics, since cellular bi-
oenergetics is a nonnegotiable necessity for tumor cell survival 
and proliferation. Therefore, we envision that targeting cancer 
metabolism and bioenergetics would provide an exciting op-
portunity on the horizon, to control human cancer.
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